Search results
Nvidia Stock, These Other Companies Make Waves As IBD Sector Leaders
Investor's Business Daily· 19 hours agoThe Denmark-based company is rivaling Eli Lilly in the weight-loss realm. Novo Nordisk also is...
William Blair Commentary: Waistlines and GLP1-s--Expanding in Unison
GuruFocus.com via Yahoo Finance· 3 days agoChanging Market Dynamics Speaking of convenience and tolerability, current GLP-1 medications sold...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
The Motley Fool via AOL· 4 days agoThat puts its efficacy at roughly...Viking additionally has another clinical-stage program testing VK2735 in a pill formation rather than as an injection. The data available ...
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
Motley Fool via Yahoo Finance· 6 days agoNovo Nordisk and Eli Lilly are the early leaders in the GLP-1 weight loss market, but that may not...
Women with excess weight at ages 14 or 31 may have higher stroke risk
MedicalNewsToday via AOL· 1 day agoResearchers say women who have excess weight at age 14 or age 31 have a higher risk of ischemic...
Ozempic Maker Novo Nordisk Stock Up More Than 31% In 2024, But Is It Too Late To Buy Shares?
Investor's Business Daily· 7 days agoTheir primary weight-loss drugs are Wegovy and Zepbound, respectively. Both are taken through weekly...
Structure Therapeutics Stock Soars on Obesity Pill Data
The Wall Street Journal· 4 days agoShares of Structure Therapeutics jumped more than 45% Monday after a new clinical study boosted...
Structure Therapeutics Stock Soars on Obesity Pill Data
The Wall Street Journal· 4 days agoStructure’s once-daily drug, code-named GSBR-1290, helped people lose an average of more than 6% of...
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors | The Motley Fool
The Motley Fool· 6 days agoEli Lilly (LLY 0.65%) and Novo Nordisk (NVO 1.87%) are the two most valuable healthcare companies in...
Heard on the Street: Wall Street Is Cheering a New Obesity Pill Candidate. Here's Why.
The Wall Street Journal· 4 days agoYou don’t need a home run to get Wall Street excited about a pill for obesity. When the market...